Vivid Global (524576)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 1.19 is moderate, with the share price ₹20.04 close to book value ₹16.77.
• Piotroski F-Score of 7/9 suggests recent fundamental improvement.
• Reported sales growth of 91.80% and profit growth of 111.11% are strong on paper; PEG of 0.30 appears cheap if growth were sustainable.
• Small market cap of ₹18 Cr keeps the business simple and avoids conglomerate complexity.

Concerns

• Latest quarter net profit is ₹0 Cr, so headline growth may be on a negligible base and is not currently converting to actual profit.
• ROE of 3.86% and ROCE of 5.58% are far below acceptable hurdle rates for a commodity chemicals business.
• P/E of 30.88 is expensive for a commodity chemicals maker, and the 0.00% dividend yield means investors get no cash while waiting.
• Key data gaps: debt/equity and promoter holding are not available, limiting balance sheet and governance assessment.

AI Analysis

At 2 minutes, let me examine Vivid Global. Price ₹20.04, market cap ₹18 Cr. I always judge a business by its return on capital. Here, ROE is 3.86% and ROCE 5.58%. That is not a wonderful business; it earns roughly ₹3.9 on every ₹100 of equity. The book value is ₹16.77, so I am paying ₹20.04 for assets earning very little. The P/E of 30.88 means I pay about 31 times last year's earnings. For a commodity chemical firm without pricing power, that is not cheap. The company reports 91.80% sales growth and 111.11% profit growth, and the PEG ratio is just 0.30. But I must be skeptical: the latest quarter shows net profit of ₹0 Cr. When profit is a rounding error, percentage growth is meaningless. A small absolute income of about ₹0.58 Cr implied by market cap and P/E can be wiped out by raw material or price changes. The Piotroski F-score is 7/9, which is decent and hints accounts are improving, but it does not compensate for weak economics. There is no dividend; the retail investor receives no cash while waiting for uncertain growth. Debt/Equity is not available, so I cannot judge leverage properly. Promoter holding is also not disclosed. In Graham's language, this is not a defensive stock. It is a tiny, commodity chemical player with poor returns, a high valuation relative to earnings, and a zero-profit latest quarter. The only attraction is that the share price is not far from book value. That limits downside if assets are real. But a 1.19 P/B and 7/9 Piotroski score are not enough. I would pass unless returns on capital improve and profitability becomes tangible. In investing, easy growth on a small base often disappears when the base grows.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer